These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21047568)

  • 1. Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.
    Thompson K; Keech F; McLernon DJ; Vinod K; May RJ; Simpson WG; Rogers MJ; Reid DM
    Bone; 2011 Jul; 49(1):140-5. PubMed ID: 21047568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.
    Silverman SL; Kriegman A; Goncalves J; Kianifard F; Carlson T; Leary E
    Osteoporos Int; 2011 Aug; 22(8):2337-45. PubMed ID: 21116816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
    Ding Y; Zeng JC; Yin F; Zhang CL; Zhang Y; Li SX; Liu X; Zhang C; Xue QY; Lin H; Pei FX
    Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.
    Billington EO; Horne A; Gamble GD; Maslowski K; House M; Reid IR
    Osteoporos Int; 2017 Jun; 28(6):1867-1874. PubMed ID: 28233020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers of inflammation after zoledronic acid redosing.
    Sykiotis A; Papaioannou G; Mavropoulos J; Triantaphyllopoulou M; Papandroulaki F; Ktena V; Thanou S; Pardalakis A; Kaltsa A; Karga H
    J Bone Miner Metab; 2014 Jan; 32(1):72-7. PubMed ID: 23690161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
    Budman DR; Calabro A
    Oncology; 2006; 70(2):147-53. PubMed ID: 16645328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of systemic treatment with aminobisphosphonates and statins on circulating Vγ9Vδ2-T cells in patients with advanced cancer.
    Schneiders FL; Huijts CM; Reijm M; Bontkes HJ; Verheul HMW; de Gruijl TD; van der Vliet HJ
    Immunobiology; 2018 Feb; 223(2):171-177. PubMed ID: 29055564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial.
    Welton JL; Morgan MP; Martí S; Stone MD; Moser B; Sewell AK; Turton J; Eberl M
    J Bone Miner Res; 2013 Mar; 28(3):464-71. PubMed ID: 23074158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
    Rossini M; Adami S; Viapiana O; Ortolani R; Vella A; Fracassi E; Gatti D
    J Bone Miner Res; 2012 Jan; 27(1):227-30. PubMed ID: 21956654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.
    De Santis M; Cavaciocchi F; Ceribelli A; Crotti C; Generali E; Fabbriciani G; Selmi C; Massarotti M
    Lupus; 2015 Apr; 24(4-5):442-7. PubMed ID: 25801887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines and insulin resistance after zoledronic acid-induced acute phase response.
    Kassi G; Papamichael K; Papaioannou G; Giagourta I; Thanou S; Triantaphyllopoulou M; Zapanti E; Papandroulaki F; Ktena V; Karga H
    Immunol Invest; 2014; 43(6):544-55. PubMed ID: 24661204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis.
    Catalano A; Morabito N; Atteritano M; Basile G; Cucinotta D; Lasco A
    Calcif Tissue Int; 2012 Apr; 90(4):279-85. PubMed ID: 22350110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
    Anastasilakis AD; Polyzos SA; Makras P; Sakellariou GT; Bisbinas I; Gkiomisi A; Delaroudis S; Gerou S; Ballaouri I; Oikonomou D; Papapoulos SE
    Bone; 2012 May; 50(5):1130-4. PubMed ID: 22366634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.
    Dhar S; Chiplunkar SV
    Cancer Immun; 2010 Nov; 10():10. PubMed ID: 21069948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group.
    Jacotot B; Banga JD; Pfister P; Mehra M
    Br J Clin Pharmacol; 1994 Sep; 38(3):257-63. PubMed ID: 7826828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of and risk factors for the acute-phase response after zoledronic acid.
    Reid IR; Gamble GD; Mesenbrink P; Lakatos P; Black DM
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4380-7. PubMed ID: 20554708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].
    Dalle Carbonare L; Bertoldo F; Lo Cascio V
    Reumatismo; 2009; 61(1):54-64. PubMed ID: 19370189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of amino-bisphosphonates on circulating γδ T cells.
    Rossini M; Adami S; Viapiana O; Fracassi E; Ortolani R; Vella A; Zanotti R; Tripi G; Idolazzi L; Gatti D
    Calcif Tissue Int; 2012 Dec; 91(6):395-9. PubMed ID: 23052225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.